Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
Open accessThe DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; none of the 86 sources its claims cite is checked for support yet.
Abstract
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence.
Overview
CoChat Summary
## TL;DR
This review argues that poor medication adherence in type 2 diabetes is common, often affecting at least half of patients, and is tied to worse glycemic control, higher costs, and higher mortality. It highlights two broad modifiable drivers: treatment burden and patients’ treatment-related beliefs.
## Key findings
- Reported poor medication adherence in T2D ranged from 38% to 93% across studies, largely because definitions and methods varied; using MPR ≥80%, adherence was 47.3% for dipeptidyl peptidase-4 inhibitors, 41.2% for sulfonylureas, and 36.7% for thiazolidinediones in a 238,000-patient MarketScan analysis.
- Poor adherence was associated with worse outcomes: among >11,000 veterans, MPR <80% was significantly associated with poor glycemic control (HbA1c >8%, P<0.001); in 1,198 survey respondents, each 1-point drop in self-reported adherence was linked to a 0.21% increase in HbA1c and increases of 4.6%, 20.4%, and 20.9% in physician, ER, and hospital visits.
- Mortality was higher with poor adherence: in 15,984 UK patients, poor adherence and missed visits were each associated with a 1.6-fold increase in all-cause mortality (P<0.001); another study reported an odds ratio of 1.8 (P<0.001).
- Economic impact was substantial: improved adherence was projected to reduce hospitalization/ER risk by 13%, worsening adherence to raise it by 15%, and one analysis estimated annual savings of $4.7 billion with improved adherence and $3.6 billion with reduced poor adherence.
## Methods
- Narrative review of the literature on medication adherence in T2D, focusing on the scope of the problem, consequences, key contributors, interventions, and future developments.
- The paper synthesizes findings from retrospective/observational claim-database studies, surveys, and meta-analyses; it cites examples including analyses of 238,000 MarketScan patients, >11,000 veterans, 1,198 survey respondents, and other large database studies.
- Main analysis is qualitative synthesis of reported adherence rates, outcomes, and modifiable contributors, with attention to common adherence metrics such as medication possession ratio (MPR) ≥80% and persistence definitions.
## Limitations
- The paper states that much of the evidence comes from retrospective or observational claim-database studies using widely varying definitions, making findings difficult to interpret.
- It states that intervention evidence is limited because adherence measures vary widely, hard outcomes are often lacking, interventions are not clearly explained, and follow-up is often inadequate.
- Evident from the text: this is a review, not a new primary study, so its conclusions depend on the quality and comparability of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 57 Not checked · 17 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In one study that tracked new prescriptions written electronically over a 12-month period for >75,000 patients, 31.4% of new prescriptions for diabetes drugs were never filled.25”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Scope of the problem
What the sources say
- Not matchedcites [25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainn = 75,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia)”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 75 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from this survey highlight patient perspectives on reasons for treatment discontinuation among people with T2DM in the USA and UK and provide focal points for communication for these individuals when they are initiating new therapies [5].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the NICE guidance (NG28) and gastrointestinal tolerability are likely important drivers, early GLP‐1RA discontinuation is plausibly multifactorial and may also reflect perceived treatment effectiveness, complex dosing schedules, injection‐related barriers, limited access to diabetes education, economic constraints, and medication shortages. 19 , 32 , 33 , 34”
From Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Up to 50% of people with T2DM discontinue treatment by 1 year [5].”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 2×
“65 A key element is the need for greater consistency when measuring medication adherence, which require better instruments and tools for assessment.”
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“Even worse, it has been well documented that this cost burden has been inexorably growing worldwide.(10) A key contributor to the remarkably high rates of morbidity and mortality is chronic poor metabolic control, especially poor glycemic control.”
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“41 In their comprehensive review of 76 studies, Claxton et al 42 found that the prescribed number of doses per day was inversely associated with medication adherence; indeed, the mean adherence across studies decreased progressively from 79% with a once-daily dose to 51% with a four times daily…”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationPrimary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions
Fischer, M. A., Stedman, M. R., Lii, J., Vogeli, C., Shrank, W. H., Brookhart, M. A., & Weissman, J. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1253-9 · Cited by 572 · cited 1×
“25 This problem, often referred to as primary nonadherence, may be particularly relevant among patients who are refusing to initiate insulin or other injectable hypoglycemic therapy, typically due to injection phobia, inconvenience, poor patient–physician communication, and/or negative patient…”
Cited by
Items 601–700 of 761
Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect
Kim, H., Park, G., Hahn, J., Oh, J., & Chang, M. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-13366-z · Cited by 1
Usman, A., Yadav, R. R., Pagare, A., Ganguly, A., & Chakrabarti, R. (2023) · Apollo Medicine · doi:10.4103/am.am_176_22 · Cited by 1
“[25] Studies have reported poor compliance in the Indian population, [26,27] warranting effective management strategies at the community and national levels.”
Banjarmasin, S. T. I. K. I., Prihandiwati, E., Yumassik, A. M., et al. (2023) · Jurnal Insan Farmasi Indonesia · doi:10.36387/jifi.v6i1.1121 · Cited by 1
Spital, U. A. E., & Khadija, R. (2018) · International Journal of Advanced Research · doi:10.21474/ijar01/6445
“According to recent surveys and reports, about half of T2D patients do not achieve adequate glycemic control (Polonsky and Henry, 2016, Ali et al., 2012, Ford 2011).”
ResultDrug Related Problems Diabetic Nephropathy Patients in a Tertiary Hospital in Malaysia
Destiani, D. P., & Ghazali, A. (2016) · Pharmacology and Clinical Pharmacy Research · doi:10.15416/pcpr.2016.1.2.42 · Cited by 1
Pharmaceutical Care in Type-2 Diabetes
Krass, I., & Hoti, K. (2018) · Springer eBooks · doi:10.1007/978-3-319-92576-9_28
Otsu, Y., Kai, M., Suematsu, Y., Kiyomi, F., Saku, K., Kamimura, H., & Miura, S.-I. (2019) · Medicine · doi:10.1097/md.0000000000015188
“In addition, in type 2 diabetes mellitus patients, a low recognition of a therapeutic effect, the appearance of hypoglycemia, and a complex dosing regimen are factors that influence the adherence to medication.([23]) The need for numerous doses reduces medication adherence.”
BackgroundTHE IMPACT OF BONE MARROW TRANSPLANTION ON PATIENTS WITH PSYCHIATRIC DIAGNOSES
Galop, B. (2020) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2020.208
Arbaein, T. J. (2020) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3423
Hot Topics in Primary Care 2020 Introduction
Brunton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0058
Review of LDL-C Lowering with Focus on New and Emerging Agents
Brinton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0070
Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician
Bakris (2020) · The Journal of Family Practice · doi:10.12788/jfp.0072
A New Era in Asthma Management: Assessment of Asthma Control
Murphy, M. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0061
Machine Learning Approaches for Type 2 Diabetes Prediction and Care ManagementPreprint
Lim, A., Singh, A. P., Chiam, J., Eckert, C., Kumar, V., Ahmad, M. A., & Teredesai, A. M. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2104.07820 · Cited by 4
Fink, A., Demuth, I., & Doblhammer, G. (2021) · Research Square · doi:10.21203/rs.3.rs-538620/v1
Chen, J., Borra, S., Fan, L., Huang, A., Patel, D. K., & Juneja, R. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107995 · Cited by 1
Williams, N. A., Brunton, S., & Scott, G. A. (2021) · Clinical Diabetes · doi:10.2337/cd21-0066 · Cited by 1
Compliance and Inertia Working Group, S. S. O. H. (.-L., Márquez‐Rivero, S., Contreras, E. M., Compliance and Inertia Working Group, S. S. O. H. (.-L., García-Ramos, L. L., Compliance and Inertia Working Group, S. S. O. H. (.-L., Castaño-Durán, C., Compliance and Inertia Working Group, S. S. O. H. (.-L., Marcos-Sánchez, A., Compliance and Inertia Working Group, S. S. O. H. (.-L., et al. (2021) · Austin Journal of Pharmacology and Therapeutics · doi:10.26420/austinjpharmacolther.2021.1141
“Non-adherence to prescribed DM2 medications are, however, common and remain a barrier to optimal health outcomes [1-5].”
BackgroundResultBhattacharyya, S., Mishra, A. B., & Khalse, M. (2021) · Indian Journal Of Applied Research · doi:10.36106/ijar/7601504
Grundlagen des Diabetesmanagements
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2022) · Der Diabetologe · doi:10.1007/s11428-022-00863-y
Adherence to Treatment of Diabetes in Patients Suffering from Co-Morbid Depression
Bokhari, S. Q., Niazi, R. A. K., Alam, R. S., Mazhar, N., Butt, A., & Bokhari, Q. M. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22162275
Kumar, Y., & Nachankar, A. S. (2022) · Journal of Marine Medical Society · doi:10.4103/jmms.jmms_71_21
Fink, A., Demuth, I., & Doblhammer, G. (2021) · Research Square · doi:10.21203/rs.3.rs-538620/v2
Willingess To Use Telehealth For Diabetes Management In The Rural Healthcare Setting
Kim, A. H. (2020) · San José State University ScholarWorks (San Jose State University) · doi:10.31979/etd.27tb-bfjp
Lailaturrahmi, L., Araswati, F., Armenia, A., & Yosmar, R. (2022) · Borneo Journal of Pharmacy · doi:10.33084/bjop.v5i2.3301
Cardiovascular outcome according to renal status in Finnish patients with type 2 diabetes
Hellman, T., Skare, O.-C., Lee, C., Wagner, U., Vikkula, J., Hällfors, J., Laatikainen, O., Lassenius, M. I., & Metsarinne, K. P. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100103
Oh, S.-H., Kim, D., Hwang, J., et al. (2022) · doi:10.2196/preprints.42190
Omer, H. A., & Omer, S. A. (2019) · University of Aden Journal of Natural and Applied Sciences · doi:10.47372/uajnas.2019.n1.a19
Kusumawardani, D. R., Lestari, F., & Yuniarni, U. (2022) · Bandung Conference Series Pharmacy · doi:10.29313/bcsp.v2i2.4106
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine
Feld, J., Tremblay, D. A., Navada, S. C., & Silverman, L. R. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2142051
“First, as MDS and AML are both diseases of the elderly [32,33], and with many patients suffering from meaningful co-morbidities [34], there is the risk of detrimental pill burden and compliance that is common with chronic diseases such as hypertension [35], diabetes [36], or other cancers including solid tumors and ch…”
BackgroundPuvvada, R. K., Tang, C. Y., Thomas, J., Kay, M., Higgs, P., Jois, M., Madhan, R., & Gupta, S. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01154-5
Sorrell, A., Stallings, T. L., & Christensen, A. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91497-0.00203-4 · Cited by 2
T2DM Patients Adherence Towards OAD Medication: A Literature Review
Oktaliani, A. D., Prajitno, J. H., & Fatmaningrum, W. (2022) · International Journal of Research Publications · doi:10.47119/ijrp1001161120234378
Grundlagen des Diabetesmanagements
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01007-6
“Dies gilt besonders für den Diabetes, bei dem häufig eine Polypharmazie mit wechselnden Dosierungen, Einnahmezeitpunkten, Neben- und Wechselwirkungen vorliegt und auch die Umsetzung von Ernährungsund Bewegungsvorsätzen oft mangelhaft ist [21].”
Presley, B., Groot, W. N. J., Setiawan, E., & Pavlova, M. (2023) · Journal of Pharmaceutical Health Services Research · doi:10.1093/jphsr/rmad025 · Cited by 1
Kok, A., Makan, H., Podgorski, G., Joshi, S., Chetty, V., Nojoko, L., Bacus, H. B., Moosa, N., & Khutsoane, D. (2023) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2023.2198348
“Reasons for this include fear of hypoglycaemia, aversion to injections and the complexity of treatment regimens.(22,32) Furthermore, the study was conducted during the initial months of the COVID-19 pandemic, when access to routine medical care appointments and medication was restricted.”
BackgroundPP, S., MSA, K., NNA, F. S., N, M., & YH, N. (2023) · Medicine & health · doi:10.17576/mh.2023.1801.19
Sultanoğlu, T. E., & Ataoğlu, S. (2023) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-023-00210-z
“In a study conducted with patients with type 2 diabetes mellitus, drug adherence was associated with stronger beliefs about the need for drugs, lower concerns about drugs, and lower beliefs about their harmful effects [36].”
BackgroundMilla-Amekor, E., & Ewusie, E. A. (2023) · Asian Journal of Medicine and Health · doi:10.9734/ajmah/2023/v21i11918 · Cited by 1
Grundlagen des Diabetesmanagements
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2075-9798
Dastjerdi, M., Sabbagh, S., Aliabadi, M. G., et al. (2026) · Journal of Iranian Medical Council · doi:10.18502/jimc.v9i2.21184
Namitha, S., & Prasannan, V. (2023) · Scholars Academic Journal of Pharmacy · doi:10.36347/sajp.2023.v12i12.007
Sinamaw, D., Belay, D. G., Chilot, D., Gela, Y. Y., Diress, M., Seid, A. M., Simegn, W., Kibret, A. A., Eshetu, H. B., Bitew, D. A., et al. (2023) · doi:10.61440/jcc.2023.v1.04 · Cited by 2
Ramos, M. L. T. (2023) · Universidad Privada San Juan Bautista · doi:10.59590/upsjb/fcs.med.hum/tesis/4837
Modeling, Estimation, and Feedback Techniques in Type 2 Diabetes
Ahdab, M. A. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau614554303
Yanovskaya, E. A., & Яновская, М. Е. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-3-13
Grundlagen des Diabetesmanagements
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01143-z
“Dies gilt besonders für den Diabetes, bei dem häufig eine Polypharmazie mit wechselnden Dosierungen, Einnahmezeitpunkten, Neben-und Wechselwirkun-gen vorliegt und auch die Umsetzung von Ernährungs-und Bewe-gungsvorsätzen oft mangelhaft ist [22].”
Kovács, R., Kotherová, Z., & Ochrana, F. (2022) · Socioekonomické a humanitní studie/Socioekonomické a humanitní studie · doi:10.61357/sehs.v15i1.24
Fundamentals of Diabetes Management
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6566
“This is particularly true for diabetes, which often involves polypharmacy with changing dosages, times of intake, side effects and interactions, and where the implementation of dietary and exercise regimens is often poor [22].”
Viñoles, F. C., Avila, J. R., Santiago, D., Vilera, N., Réquiz, Z. A., & Camperos, P. (2023) · Diabetes actual · doi:10.61156/2023.1.1.001
De-intensification as a new trend in the treatment of type 2
Yanovskaya, E. A., Яновская, М. Е., & Kaletnik, E. I. (2024) · FOCUS Endocrinology · doi:10.62751/2713-0177-2024-5-2-15 · Cited by 1
momeni, S. F., Shirinkam, F., mohamadi, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4649121/v1
Reversal of type 2 diabetes mellitus through integrated Ayurveda dietary protocol – A case report
Kumari, S., Tubaki, B. R., Patil, R. S., & Laxmikant, S. D. (2024) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2024.100946 · Cited by 5
“[2] which is often attributed to poor adherence to oral hypoglycemic agents [3] primarily due to their adverse events [4].”
Panthi, S. (2024) · Preprints.org · doi:10.20944/preprints202408.0382.v1
Nørlev, J. T. D., Kronborg, T., Hejlesen, O. K., Jensen, M. H., Vestergaard, P., & Hangaard, S. (2024) · Studies in health technology and informatics · doi:10.3233/shti240349
HbA1c Point-of-Care Testing and its Role in the Management of Diabetes
Fountain, C., Nayak, A., Sham, T. A., Sidhu, S., Popal, O., Giulani, D., Shishodia, R., Santander, D., Kilic, S., & Perryment, G. (2024) · Journal of the Osteopathic Family Physicians of California · doi:10.58858/030101
Lo, F. M. W., Wong, E. M. L., Lam, K. K. W., Liu, Q., Yang, F., Jiang, L., Huang, X., & Ho, K. Y. (2024) · Journal of Advanced Nursing · doi:10.1111/jan.16511 · Cited by 2
Grundlagen des Diabetesmanagements
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2381-6271
Medication Compliance and Affecting Factors in Elderly Type 2 Diabetic Patients in Turkey
Karakurt, P., & Mesut, I. (2024) · Clinical Journal of Nursing Care and Practice · doi:10.29328/journal.cjncp.1001057
Bloodmeter: Application for Data Acquisition and Analysis in Diabetes Patients
Ramos, D. V., Grisales, J. M., & Beltran, M. (2024) · International Congress of Biomedical Engineering and Bioengineering (CIIBBI) · doi:10.1109/ciibbi63846.2024.10784932
“Medical-patient communication is a cornerstone focused on ensuring proper patient adherence to their treatment [1] [2] [3].”
Grundlagen des Diabetesmanagements
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2025) · Die Diabetologie · doi:10.1007/s11428-024-01283-w
Huda, R. K., Singh, J., Sangwan, R. K., Kumar, P., Mandhana, L., Kumar, M., & Babu, B. V. (2025) · Cureus · doi:10.7759/cureus.81218 · Cited by 1
“This is consistent with previous research, which suggests that medication adherence is critical to effective diabetes management and improved glycemic control [10].”
Subramanian, D. A., Chin, A., Shi, Y., Liu, G. W., Langer, R., & Traverso, G. (2025) · ACS Nano · doi:10.1021/acsnano.4c13520
Iqbal, M. Z., Alqahtani, S. S., Shahid, S., & Orayj, K. M. (2025) · Healthcare · doi:10.3390/healthcare13080901 · Cited by 2
“Control relies not only on physician adherence to clinical guidelines for managing disease but also significantly on patient compliance with prescribed pharmaceutical regimens [2].”
Mohapatra, P., DEBATA, A., Kar, D. M., & Rath, K. (2025) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2025v18i4.54152 · Cited by 1
“therapy, and the specifics of their regimen [11].”
Tan, X., Brady, B. L., Xie, L., & Paprocki, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01741-8
“…this study also highlights a “gap in care” in the discontinuer cohort, potentially indicating not only a specific patient behavioral issue [52] but also the possibility of a wider systemic healthcare issue in the continuum of treatment for patients for whom a specific GLP-1 RA treatment…”
Sheikh, A., Parvin, S., Dipto, S., & Hossain, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.13.653885
Extreme Temperature And Other Environmental Factors On Diabetes Admissions
Gao, D. (2024) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/6wcy-bh0v
Hari, V., & Thajuddeen, K. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0999
Yanovskaya, E. A., & Яновская, М. Е. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-2-08
Tupinambá, G. D. S., de Aguiar, O. B., de Moura, B. P., Schmidt, M. I., Molina, M. D. C. B., Griep, R. H., & da Fonseca, M. D. J. M. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240867 · Cited by 2
“36 É importante ressaltar que uma boa adesão está associada a um melhor controle glicêmico, com pacientes com alta adesão apresentando 1,33 vezes mais chances de atingir um bom controle em comparação aos pacientes com baixa adesão.”
Tupinambá, G. D. S., de Aguiar, O. B., de Moura, B. P., Schmidt, M. I., Molina, M. D. C. B., Griep, R. H., & da Fonseca, M. D. J. M. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240867i
Štochl, J., Clarke, N. A., Green, D., Comins, J. D., Higgins, V., Piercy, J., Arbuckle, R., Halasa, T., da Rocha, T. J. C. M., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16551
Importance of medication adherence for better quality of life in diabetes patients
Narne, H. M., Thangabalan, B., Patra, R., Panda, A., Kadala, S., Talam, U. S. D., Kanaparthi, S., & Miriyala, A. (2025) · International Journal of Pharmacognosy and Pharmaceutical Sciences · doi:10.33545/27067009.2025.v7.i2a.170
Tang, T., Stoecker, C., Winberg, D., Liu, M., Nauman, E., Cong, M., Price‐Haywood, E. G., Mohundro, B. L., Bazzano, A. N., Shi, L., et al. (2025) · Value in Health · doi:10.1016/j.jval.2025.07.017
Nabi, N., Khan, M. N., Raza, S., Tariq, M. O., Tahir, A. B., Ifunanya, O. V., Ibadin, S. O., & Yousaf, F. (2025) · Cureus · doi:10.7759/cureus.89639 · Cited by 2
“Particularly at risk are the elderly and those who have had their illnesses for a longer period of time [9,10].”
Ansari, P., Islam, S. S., Ali, A., Masud, M. S. R., Reberio, A. D., Khan, J. T., Hannan, J. M. A., Flatt, P. R., & Abdel‐Wahab, Y. H. A. (2025) · Diabetology · doi:10.3390/diabetology6080083
amin, M. A. H., Ratha, R., & Mahwi, T. (2025) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v9i1.2339
“Furthermore, poor adherence increases healthcare costs due to more frequent clinic visits, emergency care, and the long-term management of diabetes-related complications [13].”
The Effectiveness of Tirzepatide on weight loss in patients with type 2 Diabetes MellitusPreprint
Olalere, M., Khawaja, M., Ndukwe, O., Khan, R., Kumar, K., Sreejith, A., Sreedharan, J., & Muttappallymyalil, J. (2025) · medRxiv · doi:10.1101/2025.09.19.25336122
The Relationship between Diabetic Patients' Health Literacy and HBA1c Level in Jordan
Bawab, A. Q. A., Al-Qerem, W. A., Jarab, A. S., Eberhardt, J., Alasmari, F. F., Hammad, A. M., Alkaee, S. M., & Alsabaa, Z. H. (2025) · Jordan Journal of Pharmaceutical Sciences · doi:10.35516/jjps.v18i3.2821
“These findings are consistent with previous studies, including cross-sectional research conducted in countries like the USA [11], Saudi Arabia [27], Ethiopia[26], Denmark [28], and South Korea [29].”
Tip 2 Diyabet Hastalarında İlaç Uyumu ve Etkileyen Faktörler
Bolukçu, F., & Yücel, Ş. (2025) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tudod.1709451
Cheng, C. W. S., Stevens, K. N., Poirier, S. E., Kodsy, M. M., Dong, O., Lee, A., & Bafus, B. T. (2025) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-23-00593
Wang, F., Luan, Z., Maltesen, R. G., Reenberg, A. T., Westergaard, L., & Liu, D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01803-x
“A combination product of basal insulin and GLP-1RA suitable for once-weekly administration could reduce the burden associated with daily dosing and may also be able to address insulin treatment inertia in individuals with T2D [7–9].”
Nageswara Rao., T., Ramesh, B., Suguna, S., et al. (2025) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v6i9.2065
Manjula, S., & Krishna Kumar, M. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_24_25 · Cited by 1
Ghyabi, F., Tabatabaei, S. V., Movahed, E., & Haji‐Maghsoudi, S. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_217_24
How the Salutogenic Pattern of Health Reflects in Type 2 Diabetes Mellitus: A Narrative Review
Mijač, S., Vitale, K., Lončarek, K., & Slivšek, G. (2025) · Diabetology · doi:10.3390/diabetology6110124 · Cited by 2
IoT's Role in Revolutionizing Pillbox Technology
Singh, S., Sharma, A., -, S., Mukund, S. C., & Sharma, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324457125010009
Lian, D., Liu, J., Wei, Y., Yang, Y., Ren, Y., Bao, S., Liu, L., Liu, S., & Chen, Y. (2025) · Patient · doi:10.1007/s40271-025-00776-0
“Treatment adherence and outcomes are often influenced by individual patient values, exploring these preferences can enable more tailored interventions, enhancing both clinical outcomes and quality of life [10, 11].”
Trust and Autonomy in the age of Digital Patient Monitoring
González, M. M. (2025) · Revista de Bioética y Derecho · doi:10.1344/rbd2025.65.49840
Reddy, P., Jha, A., Gupta, H., Verma, V., Kumar, D., Bansal, A. K., Mahapatra, S., Rehman, T., Parida, S. K., Jena, M., et al. (2025) · Trials · doi:10.1186/s13063-025-09209-7 · Cited by 2
Impact of telehealth nutrition therapy on costs and utilization in type 2 diabetes & obesityPreprint
Shanmugam, P., Adams, R. N., Athinarayanan, S. J., Wolfberg, A., & Ballreich, J. M. (2025) · medRxiv · doi:10.1101/2025.11.09.25339829
Hassanein, M. M., Alessa, T., Hafidh, K., Alzubaidi, L. M. Y., Jallo, M. K. I., Slail, F. Y. A., Elbadawi, H., & Malik, R. A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01824-6
“Such regimens are especially challenging for older or frail individuals who may already be struggling with self-management [24] and are associated with reduced medication adherence [25].”
Debnath, S., Purohit, S., Singh, A. K., Pal, P., Rajotiya, S., Mishra, S., Nakash, P., Kumar, S., Paul, S., Sharma, A., et al. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.12.011
“8,10 These factors may collectively contribute to reduced motivation and greater hesitancy toward insulin adherence in type 2 diabetes.”
Okeke, J. I., Oyediran, K. O., & Joda, A. E. (2025) · Discover Public Health · doi:10.1186/s12982-025-01264-4
“Poor medication adherence worsens disease progression, increases complications, healthcare utilization, and costs, disability and mortality [34].”
Grundlagen des Diabetesmanagements
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-7737
Preclinical pharmacological profiles of cofrogliptin, a novel and bi-weekly DPP-4 inhibitor
Gou, X., 窦彩霞, Tang, P., Zheng, X., Zhang, C., Wang, J., Meng, Q., & Wang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1702101
Agarwal, V., GUPTA, M., Awasthi, R., Chandra, K. P., Gupta, N. R., Chaubey, S. K., Pande, A. K., & Kumar, D. (2026) · Cureus · doi:10.7759/cureus.100966
“Suboptimal adherence is consistently linked to poor outcomes, including increased complications and higher healthcare costs [4].”
Dwiastuti, A., Latarissa, I. R., Hidayat, A., Halimah, E., & Lestari, K. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s561759 · Cited by 2
Boykins, A. M., Mahmood, A., Wicks, M. N., Surbhi, S., Martinez, S. A., Stentz, F. B., & Bailey, J. E. (2026) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2026.101597 · Cited by 1
“…of intensive medication therapy aimed at reducing glucose, cholesterol, and blood pressure levels among patients with T2D has yielded modest results at best [4], largely due to the complexities of navigating medication burden, particularly among vulnerable and medically underserved populations [5].”
Metadata
- Authors
- Polonsky, W., & Henry, R.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Polonsky, William
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- Volume 10
- Pages
- 1299-1307
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC4966497
- OpenAlex
- W2493860075
- Cited by
- 784
- References
- 77
- Citations by year
- 2026: 93 · 2025: 97 · 2024: 89 · 2023: 82 · 2022: 108 · 2021: 106 · 2020: 106 · 2019: 54 · 2018: 34 · 2017: 13 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- medication adherence, type 2 diabetes, glycemic control, barriers to adherence, medication beliefs, medication burden, out-of-pocket costs, hypoglycemia, treatment complexity, clinical inertia, socioeconomic factors, diabetes complications, drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.